Thank you to our speakers, sponsors, and delegates who joined us in Barcelona for the summit! If you are interested in the 2026 event, please get in touch at info@hansonwade.com
While Infant Bacterial Therapeutics pushed towards pharmaceutical registration, MRM Health pioneers lived microbial consortium therapies for IBD and Microbiotica accelerated into the clinic with assets for advanced melanoma and UC. The microbiome biotech pipeline was overflowing with compelling data, increasingly validating the transformative potential of microbiome-based therapies across diverse disease areas.
With the first LBP approvals on the horizon, but financial pressures threatening to slow progress, the 9th Microbiome Movement Summit Europe returned to Barcelona in January as the essential industry hub for R&D and business leaders determined to push the field forward.
The Summit explored the latest advances in microbiome science, where innovative biotechs were uncovering new microbial targets, deciphering mechanisms of action and harnessing state-of-the-art analytical tools to uncover the microbiome’s role in disease. Attendees engaged with investors and C-level leaders as our producers strategised how to bring big pharma back into the fold of emerging microbial modalities.

New Additions In 2025
You Got Closer to Clinical Readouts
You heard first-hand from industry leaders including Seres Therapeutics, MRM Health, and EXELIOM Biosciences as they revealed key insights into advancing LBP candidates and shared new clinical data.
You Navigated Paths to Clinical Readiness
You discovered how Microbiotica has tackled regulatory hurdles head-on, ensuring that you were prepared to anticipate CMC challenges and secure the funding needed to reach Phase I. You learned from BioGaia Pharma and Luca Bio on innovative business models where consumer-stage candidates fast tracked therapeutics programmes back into drug development, offering a new way to navigate financial pressures while advancing R&D.
You Explored Cutting-Edge Analytics & Emerging Modalities
From Kanvas Biosciences’ use of spatial biology to optimise consortia selection, to PharmaBiome’s big data-driven predictions of in-human responses, analytical innovation was moving fast. You were inspired by Prokarium’s programmable bacteria and Intrinsic Medicine’s research to target the gut-brain axis, which helped to gain crucial therapeutic landscape insights to sharpen your competitive edge.
2025 Speaker Faculty Included:


Gabriela Juárez Martínez
Innovation Lead – AMR & Microbiome Innovate UK Business Connect
Independent



What Our Attendees Said:
2025 Partners:
Lead Partner

Expertise Partners


Innovation Partner


Exhibition Partner



Event Partner
